Find Zoliflodacin manufacturers, exporters & distributors on PharmaCompass

Zoliflodacin

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

DIGITAL CONTENT

4 NEWS #PharmaBuzz

media
4 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1620458-09-4, Azd0914, Azd-0914, Zoliflodacin [usan], Etx0914, Etx-0914

Molecular Formula

C₂₂H₂₂FN₅O₇

Molecular Weight

487.4 g/mol

InChI Key

ZSWMIFNWDQEXDT-ZESJGQACSA-N

FDA UNII

FWL2263R77

Zoliflodacin has been used in trials studying the basic science and treatment of Gonorrhoea.

1 2D Structure

Zoliflodacin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione

2.1.2 InChI

InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1

2.1.3 InChI Key

ZSWMIFNWDQEXDT-ZESJGQACSA-N

2.1.4 Canonical SMILES

CC1CN2C(C(O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6C(COC6=O)C)C(=O)NC(=O)NC3=O

2.1.5 Isomeric SMILES

C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O

2.2 Other Identifiers

2.2.1 UNII

FWL2263R77

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'h,3'h)-trione

2. Azd-0914

3. Azd0914

4. Etx-0914

5. Etx0914

2.3.2 Depositor-Supplied Synonyms

1. 1620458-09-4

2. Azd0914

3. Azd-0914

4. Zoliflodacin [usan]

5. Etx0914

6. Etx-0914

7. Fwl2263r77

8. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'h,3'h)-trione

9. Unii-fwl2263r77

10. Zoliflodacin(azd0914)

11. Zoliflodacin (usan/inn)

12. Zoliflodacin [inn]

13. Zoliflodacin [who-dd]

14. Azd 0914 - Bio-x

15. Chembl3544978

16. Schembl15879500

17. Gtpl10875

18. Azd0914etx0914

19. Ext0914

20. Bdbm139376

21. Dtxsid101028418

22. Azd 0914

23. Ex-a2620

24. Ext-0914

25. Etx0914; Azd0914; Zoliflodacin

26. Db12817

27. Ac-35757

28. Ba164192

29. Hy-17647

30. Cs-0016917

31. D11726

32. Us8889671, 5

33. Q27278240

34. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((s)-4-methyl-2-oxooxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(1'h,3'h)-trione

35. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((s)-4-methyl-2-oxooxazolidin-3-yl)-2,4,4a,6-tetrahydro-1h,1'h-spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(3'h)-trione

36. (4'r,6's,7's)-17'-fluoro-4',6'-dimethyl-13'-[(4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione

37. (7s,11r,13s)-3-((4s)-2-oxo-4-methyltetrahydrooxazole-3-yl)-9-fluoro-11,13-dimethyl-8,7-(ethanoxymethano)-7,8,1',2',3',4'-hexahydrospiro[isoxazolo[4,5-g]quinoline-6(5h),5'(6'h)-pyrimidine]-2',4',6'-trione

38. Spiro(isoxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5(6h),5'(2'h)-pyrimidine)-2',4',6'(1'h,3'h)-trione, 11-fluoro-1,2,4,4a-tetrahydro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-3-oxazolidinyl)-, (2r,4s,4as)-

2.4 Create Date

2014-08-04

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₂FN₅O₇
Molecular Weight	487.4 g/mol
XLogP3	1.3
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	1
Exact Mass	487.15032622 g/mol
Monoisotopic Mass	487.15032622 g/mol
Topological Polar Surface Area	143 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	962
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of gonococcal infection

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)

Drugs in Development